SLC16A1 and neoplasm: These metabolic changes could suggest that simvastatin-treated tumours rely on oxidative phosphorylation and resort to the upregulation of MCT1 expression as a compensatory mechanism for survival, consistent with the role of MCT1 an importer of mitochondrial fuels24.